Seilong Pharmaceutical’s subsidiary, Famotidine, receives approval for launching
January 6, 2025
Source: drugdu
43
Financial Update, January 1 - Seilong Pharmaceutical (002898) announced that its wholly-owned subsidiary, Hunan Seilong Pharmaceutical Co., Ltd., has recently received the approval notification for the listing application of Famotidine from the National Medical Products Administration. The valid period for this drug is 18 months, and the notification is effective until December 30, 2029, with a registration standard number of YBY77052024. Famotidine is primarily used to treat upper gastrointestinal bleeding caused by peptic ulcers, further enriching the company’s raw material pharmaceutical product pipeline. The company stated that specific production and sales conditions will be influenced by various internal and external environmental changes, which may lead to certain uncertainties. In the first three quarters of 2024, Seilong Pharmaceutical achieved revenue of 219 million yuan, with a net profit attributable to the parent company of -3.69 million yuan.
https://finance.eastmoney.com/a/202501013284575136.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Sold for 4.5 billion! Why is another state-owned enterprise taking control of traditional Chinese medicine after selling medicine? January 7, 2025
- Did the new drug cost so much money and go to the wrong place? January 7, 2025
- Baide Medical’s stock surged 624% January 7, 2025
- Developing Protein based Artificial Neural Networks January 7, 2025
- Novartis accused of commercial bribery January 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
